Table 4.

Mean values and standard deviations of variables analyzed before and during chemotherapy in CP + bevacizumab patients

Parameter	CP + bevaciumab
	Before chemotherapy	I administration	II administration	III administration	IV administration	p
D-dimers, ng/mL	1747.72 ± 1772	1144.27 ± 1193.17	1126.27 ± 1281.18	990 ± 1155.91	942 ± 1127.77	0.02
Leukocytes, G/L	6.9 ± 2.39	7.51 ± 2.24	8.28 ± 2.33	6.79 ± 4.02	6.87 ± 2.3	0.04
PLT, G/L	296.47 ± 104.33	309.24 ± 120.41	255.24 ± 64.32	193.35 ± 68.04	279.88 ± 130.8	0.001
Hb, mmol/L	6.98 ± 0.67	7.02 ± 0.7	6.94 ± 0.51	6.89 ± 0.66	6.82 ± 0.54	0.15
APTT, s	28.66 ± 2.42	30.21 ± 1.84	29.82 ± 3.04	29.63 ± 2.94	29.54 ± 2.5	0.56
PT, s	12.62 ± 1.37	12.2 ± 1.18	11.94 ± 1.1	11.77 ± 1.15	11.8 ± 1.25	0.03
INR	1.07 ± 0.09	1.92 ± 3.02	1.03 ± 0.06	1.04 ± 0.09	1.03 ± 0.07	0.13
Fibrinogen, g/L	3.7 ± 1.04	3.42 ± 0.83	3.4 ± 0.99	3.41 ± 0.99	3.56 ± 1.25	0.19

PLT blood platelets, Hb hemoglobin, APTT activated partial thromboplastin time, PT prothrombin time, INR international normalized ratio